Therapeutic effect of sorafenib on portal hypertension:research progress and mechanisms
- VernacularTitle:索拉非尼对门静脉高压症的治疗作用及其机制
- Author:
Yun ZHU
1
;
Yang CHENG
;
Aimin LI
;
Rongcheng LUO
Author Information
1. 南方医科大学中西医结合肿瘤中心
- Keywords:
portal hypertension;
sorafenib;
hemodynamics;
hepatic stellate cell;
angiogenesis
- From:
Journal of Southern Medical University
2014;(1):133-136
- CountryChina
- Language:Chinese
-
Abstract:
Portal hypertension, as one of the major complications of liver cirrhosis, is a common clinical syndrome characterized by an increased portal pressure and the formation of portal-systemic collaterals. Currently no ideal therapeutic agent has been available for portal hypertension. Sorafenib is an oral tyrosine kinase inhibitor that has been shown to significantly improve blood flow dynamics, inhibit angiogenesis, reduce liver fibrosis and decrease portal pressure in the treatment of portal hypertension. The authors review the progress in the research of sorafenib in the treatment of portal hypertesion and the mechanisms of its actions.
